Management tracks: Vifor, Kintai, Verge, Xellia, Syapse

Vifor Pharma Ltd. (SIX:VIFN) said Sanofi’s Klaus Henning Jensen will become CMO and a member of the executive committee, effective in January. A three-year veteran of the French pharma, Jensen has served as global therapeutic area head for diabetes, cardiovascular & metabolism development at the pharma since January. Vifor also said CCO Dario Eklund is leaving the renal, hematologic and infectious disease company at the end of September to pursue another opportunity. A search for a successor is under way.

Mark Nuttall is joining Kintai Therapeutics Inc. (Cambridge, Mass.) as CBO. Nuttall was CBO of Kymera Therapeutics Inc. (Cambridge, Mass.). Kintai is developing tissue-targeted oral small molecules that mimic microbes’ therapeutic effects (see "Kintai’s Host-targeting Niche in Flagship Microbiome Ecosystem")...